<b>Background:</b> Human epidermal growth factor receptor 2 (HER2) alterations have been implicated as mechanisms of resistance to anti-epidermal growth factor receptor (anti-EGFR) therapy in metastatic colorectal cancer (mCRC). The gene discussed is ERBB2; the disease is metastatic colorectal cancer.